- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
GlaxoSmithKline PLC (G1SK34)
GlaxoSmithKline PLC stock price live, this page displays BVMF G1SK34 stock exchange data. View the G1SK34 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the GlaxoSmithKline PLC real time stock price chart below.
What Is the GlaxoSmithKline PLC Stock Price Today?
The GlaxoSmithKline PLC stock price today is 41.60.
What Is the Stock Symbol for GlaxoSmithKline PLC?
The stock symbol for GlaxoSmithKline PLC is ""G1SK34.""
What Stock Exchange Does GlaxoSmithKline PLC Trade On?
GlaxoSmithKline PLC is listed and trades on the B3 stock exchange.
Is GlaxoSmithKline PLC a Good Stock to Buy?
Determining whether GlaxoSmithKline PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the G1SK34 quote. (ISIN: BRG1SKBDR008)
What Is the GlaxoSmithKline PLC Stock Price Today?
The GlaxoSmithKline PLC stock price today is 41.60.
What Is the Stock Symbol for GlaxoSmithKline PLC?
The stock symbol for GlaxoSmithKline PLC is ""G1SK34.""
What Stock Exchange Does GlaxoSmithKline PLC Trade On?
GlaxoSmithKline PLC is listed and trades on the B3 stock exchange.
Is GlaxoSmithKline PLC a Good Stock to Buy?
Determining whether GlaxoSmithKline PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the G1SK34 quote. (ISIN: BRG1SKBDR008)
41.60
-0.74(-1.75%)
Closed·
Fair Value
An estimate of a GlaxoSmithKline's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
41.60
41.60
52 wk Range
37.88
49.06
G1SK34 Scorecard
Full Analysis
Net income is expected to grow this year
High dividend Yield
Fair Value
An estimate of a GlaxoSmithKline's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
41.6041.60
52 wk Range
37.8849.06
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(4.25%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(4.25%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
G1SK34 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a GlaxoSmithKline's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings downwards for the upcoming period
- Form 6K GSK plc DRC For: 23 July
- Investing.com
- Form 6K GSK plc DRC For: 18 July
- Investing.com
- Form 6K GSK plc DRC For: 23 July
- Investing.com
- Glaxosmithkline receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
GlaxoSmithKline PLC Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
Compare G1SK34 to Peers and Sector
Metrics to compare | G1SK34 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipG1SK34PeersSector | |
|---|---|---|---|---|
P/E Ratio | 17.8x | 17.2x | −0.5x | |
PEG Ratio | −0.58 | 0.10 | 0.00 | |
Price/Book | 4.0x | 3.0x | 2.6x | |
Price / LTM Sales | 1.8x | 2.7x | 3.2x | |
Upside (Analyst Target) | - | 30.2% | 41.7% | |
Fair Value Upside | Unlock | 32.7% | 6.1% | Unlock |
Earnings
Latest Release
Apr 30, 2025
EPS / Forecast
0.39 / --
Revenue / Forecast
7.52B / --
FAQ
What Stock Exchange Does GlaxoSmithKline Trade On?
GlaxoSmithKline is listed and trades on the B3 Stock Exchange stock exchange.
What Is the Stock Symbol for GlaxoSmithKline?
The stock symbol for GlaxoSmithKline is "G1SK34."
What Is the GlaxoSmithKline Market Cap?
As of today, GlaxoSmithKline market cap is 420.27B.
What Is GlaxoSmithKline's Earnings Per Share (TTM)?
The GlaxoSmithKline EPS (TTM) is 0.77.
From a Technical Analysis Perspective, Is G1SK34 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has GlaxoSmithKline Stock Split?
GlaxoSmithKline has split 1 times.
How Many Employees Does GlaxoSmithKline Have?
GlaxoSmithKline has 68629 employees.
What is the current trading status of GlaxoSmithKline (G1SK34)?
As of 26 Jul 2025, GlaxoSmithKline (G1SK34) is trading at a price of 41.60, with a previous close of 42.34. The stock has fluctuated within a day range of 41.60 to 41.60, while its 52-week range spans from 37.88 to 49.06.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.